Gilead reports positive long-term data for Yescarta for NHL (NASDAQ:GILD)

Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL.

The analysis showed that after a median follow-up of more than